Dear Editor, Cutaneous plasmacytosis (CP) is characterized by a reactive proliferation of mature plasma cells in the skin. 1 Several therapeutic modalities have been reported, with varying effects. We present a case of CP successfully treated with 308-nm excimer lamp.In December 2015, a 74-year-old Japanese man was referred to us because of an 18-month history of gradually Figure 1. (a) The patient, a 74-year-old man. On his trunk, 10-15-mm multiple infiltrating erythemas had presented. (b) The 311-nm narrowband ultraviolet B (NBUVB) therapy was performed once a week at an initial irradiation dose of 0.2 J/cm 2 . The dose was gradually increased at each visit, and reached 0.8 J/cm 2 20 weeks after the start of treatment. In March 2017, the 311-nm NBUVB therapy at a total 58 J/cm 2 showed only a slight effect on the cutaneous plasmacytosis (CP). (c) The 308-nm excimer lamp therapy was performed once a week at an initial irradiation dose of 100 mJ/cm 2 . The dose was gradually increased at each visit, and reached 220 mJ/cm 2 12 weeks after the start of treatment. In November 2017, the 308-nm excimer lamp therapy at a total of 9 J/ cm 2 showed a full effect on the CP. No obvious adverse events were observed. (d,e) Perivascular, periadnexal and lobular infiltrations of mature plasma cells were observed in the dermis to subcutaneous fat, histopathologically (hematoxylin-eosin, [d] scanning magnification, [e] 9400). (f,g) No light chain restriction was detected by in situ hybridization for Igj-and Igk-chain (j/k ratio, 0.6; [f] Igj 9200; [g] Igk 9200).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.